Bluebird in fundraising mode: A $150M public offering and a deal to get cash early from gene therapy sales
Facing a financial void it had hoped to be filled by a priority review voucher, bluebird bio is tapping two different sources to bring in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
